Nkarta Inc Total Liabilities
Nkarta Inc total liabilities. Based on the latest financial reports, Nkarta Inc (NKTX) has total liabilities worth $89.91 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NKTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nkarta Inc (2018–2025)
Total liabilities of Nkarta Inc from 2018 to 2025. This chart illustrates how Nkarta Inc's total liabilities have evolved over time, based on quarterly financial data. Explore NKTX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Nkarta Inc Competitors by Total Liabilities
The table below lists competitors of Nkarta Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jw Life Science Corp
KO:234080
|
Korea | ₩79.02 Billion |
|
Sigachi Industries Limited
NSE:SIGACHI
|
India | Rs3.12 Billion |
|
WCT Holdings Bhd
KLSE:9679
|
Malaysia | RM4.83 Billion |
|
Hung -Gu Oil Ltd
KQ:024060
|
Korea | ₩14.29 Billion |
|
Sam Young Chem
KO:003720
|
Korea | ₩112.72 Billion |
|
Apyx Medical Inc
NASDAQ:APYX
|
USA | $49.98 Million |
|
MTM Critical Metals Ltd
AU:MTM
|
Australia | AU$13.94 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Nkarta Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nkarta Inc total assets.
Liquidity & Leverage Metrics
Nkarta Inc Total Liabilities Ratios Explained
Nkarta Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nkarta Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nkarta Inc (2018–2025)
The table below shows the annual total liabilities of Nkarta Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $91.88 Million | -1.44% |
| 2024-12-31 | $93.23 Million | -11.72% |
| 2023-12-31 | $105.60 Million | +4.83% |
| 2022-12-31 | $100.73 Million | +339.18% |
| 2021-12-31 | $22.94 Million | +39.60% |
| 2020-12-31 | $16.43 Million | -77.77% |
| 2019-12-31 | $73.89 Million | +392.59% |
| 2018-12-31 | $15.00 Million | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more